Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLEDYL (oxtriphylline) is an oral solution xanthine bronchodilator indicated for respiratory conditions such as asthma and COPD. Oxtriphylline is a choline salt of theophylline that works by relaxing airway smooth muscle and improving bronchial airflow. The product is currently in pre-launch phase under Pfizer's sponsorship.
Pre-Launch
Pre-launch stage indicates nascent commercial infrastructure; team size and budget allocation remain undetermined pending regulatory clearance and market entry strategy.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHOLEDYL is a pre-launch asset with minimal current hiring activity, reflecting early development stage. Career opportunities will materialize upon regulatory approval and commercial launch, primarily in regulatory, brand management, and field-based roles.
Regulatory Affairs ManagerBrand Manager
Worked on CHOLEDYL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.